Welcome to our dedicated page for Zimmer Biomet news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet stock.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) is a global medical technology company focused on musculoskeletal health, orthopedic implants and digital and robotic technologies. This news page aggregates company announcements, press releases and market-facing updates so readers can follow how Zimmer Biomet develops and commercializes its orthopedic, trauma and digital care offerings.
Recent news highlights include earnings announcements and conference call webcasts, where Zimmer Biomet reports quarterly financial results and discusses performance across product categories such as knees, hips, sports medicine, extremities, trauma and technology and data, bone cement and surgical. The company also issues updates on its capital allocation, including quarterly cash dividends approved by its Board of Directors.
Zimmer Biomet frequently announces product and technology milestones. Examples include U.S. FDA 510(k) clearance for an enhanced version of its ROSA Knee robotic technology, FDA Breakthrough Device Designation for an iodine-treated total hip replacement system, and launches of new foot and ankle trauma solutions through its Paragon 28 business. The company also reports collaborations and integrations, such as the use of mobility intelligence technology within its mymobility care management platform, and highlights its broader connected care strategy linking robotics, digital platforms and analytics.
Investors and observers can also find updates on Zimmer Biomet’s participation in major healthcare and investor conferences, as well as news related to acquisitions like the merger with Monogram Technologies Inc. Bookmark this page to review the latest official communications from Zimmer Biomet on its orthopedic portfolio, digital and robotic technologies, financial disclosures and strategic initiatives.
Zimmer Biomet Holdings (NYSE: ZBH) will host its third quarter earnings conference call on November 6, 2020, at 8:30 a.m. ET. A news release with detailed financial results will be available earlier that day at 6:30 a.m. ET. Investors can access the live webcast through the Investor Relations website. For those in the U.S. and Canada wishing to participate via phone, call (888) 312-9837 using conference ID 7278985. A digital recording will be accessible from November 6, 2020, to January 10, 2021.
Zimmer Biomet Holdings has declared a quarterly cash dividend of $0.24 per share for Q3 2020. This dividend will be payable on or about October 30, 2020 to stockholders who are on record as of the close of business on September 30, 2020. The commitment to returning value to shareholders reflects the company's confidence in its financial position and ongoing operations in the musculoskeletal healthcare sector.
Zimmer Biomet Holdings (NYSE: ZBH) announced that President and CEO Bryan Hanson and CFO Suky Upadhyay will present at the Morgan Stanley Virtual Global Healthcare Conference on September 15, 2020, at 2:00 p.m. ET. A live webcast will be available on the company’s Investor Relations website, with an archived replay option. Founded in 1927 and based in Warsaw, Indiana, Zimmer Biomet specializes in musculoskeletal healthcare, offering a variety of orthopedic and surgical products worldwide.
Zimmer Biomet Holdings (NYSE: ZBH), a leader in musculoskeletal healthcare, will present at the Wells Fargo 2020 Virtual Healthcare Conference on September 9, 2020, at 11:20 a.m. ET. The presentation will feature President and CEO Bryan Hanson and Executive VP and CFO Suky Upadhyay. A live webcast of the event can be accessed via Zimmer Biomet's Investor Relations website and will be archived for future viewing. Founded in 1927, Zimmer Biomet is headquartered in Warsaw, Indiana, and operates globally in the orthopedic market.
Zimmer Biomet reported Q2 2020 net sales of $1.226 billion, a 38.3% decrease year-over-year. The company faced a net loss of $206.6 million, with adjusted net earnings of $10.2 million. The diluted loss per share was $1.00, with adjusted diluted EPS at $0.05, down 97.4% from the previous year. The ongoing impact of COVID-19 significantly affected elective procedures, with notable declines in sales across all regions and product categories. Despite recovery signs, uncertainty hampers future guidance.
Zimmer Biomet Holdings, Inc. (ZBH) will host its second quarter earnings conference call on August 4, 2020, at 8:30 a.m. ET. A news release detailing the quarterly results will be available at 6:30 a.m. ET on the same day. The call can be accessed via Zimmer Biomet's Investor Relations website, and a digital recording will be available from August 4 to October 4, 2020. For U.S. and Canada participants, the call can be joined by dialing (888) 312-9837 with conference ID 7278985.
Zimmer Biomet Holdings (NYSE: ZBH) introduces new features to its mymobility platform with Apple Watch, enhancing remote care management for joint replacement patients. The upgrade includes gait quality metrics, which provide real-time patient data and improve post-operative care management. These updates aim to optimize patient experience and reduce in-office visits. The new features will be showcased at the virtual WWDC 2020 from June 22 to 26, 2020, and will be available later this year. This digital transformation prioritizes effective patient management in the current healthcare landscape.